C. Grison et al.
SHORT COMMUNICATION
threo (740 mg, 1.53 mmol) using the general hydrogenation–acety-
lation protocol described above (40 bars of H2 for 18 h) to obtain
intermediate 13-d-threo (465 mg, 100%). Next, 13-d-threo (465 mg,
1.53 mmol) was acetylated to afford 14-d-threo (431 mg, 81%) as a
white solid. M.p. 165–166 °C (ref.[31] 163–165 °C). Rf = 0.42
(EtOAc/MeOH, 19:1). [α]2D3 = –53.3 (c = 1.05, CHCl3) {ref.[31]
threo, l-erythro, and d-threo, we moved to the synthesis of
target 14-d-erythro and its C-6 epimer. For that purpose,
aminodiols 9-d-threo and 9-d-erythro were used as sub-
strates in the protocol presented in Scheme 6. First, both 9-
d-threo and 9-d-erythro were tosylated using standard con-
ditions to afford desired tosylated intermediates 11-d-threo
and 11-d-erythro in acceptable yields. Those compounds
were found to be very unstable, and therefore, they were
immediately reduced with LiAlH4 to produce desired prod-
1
[α]2D3 = –59.0 (c = 5.3, CHCl3)}. H NMR (400 MHz, CDCl3): δ =
6.13 (d, JH9,H6 = 6.7 Hz, 1 H, H9), 5.29 (d, JH1,H2 = 5.0 Hz, 1 H,
H1), 4.62 (dd, JH3,H4 = 8.0 Hz, JH3,H2 = 2.2 Hz, 1 H, H3), 4.38
(dd, JH4,H3 = 8.0 Hz, JH4,H5 = 1.5 Hz, 1 H, H4), 4.29 (dd, JH2,H1
ucts 12-d-threo and 12-d-erythro in good overall yields. = 4.9 Hz, JH2,H3 = 2.2 Hz, 1 H, H2), 4.21 (dd, JH5,H6 = 6.4 Hz,
JH5,H4 = 1.5 Hz, 1 H, H5), 4.17 (dd, JH7,H8 = 6.6 Hz, JH7,H6
=
Subsequent hydrogenation of compounds 12-d-threo and
12-d-erythro resulted in quantitative formation of desired
debenzylated intermediates 13, which were directly pro-
tected by acetylation to produce the final target com-
pounds, that is, 14-d-erythro and its C-6 epimer 14-d-threo,
in good yields.
2.3 Hz, 1 H, H7), 3.78–3.73 (m, 1 H, H6), 2.05 (s, 3 H, H11), 1.54
(s, 3 H, CH3), 1.46 (s, 3 H, CH3), 1.34 (s, 3 H, CH3), 1.32 (s, 3 H,
CH3), 1.18 (d, JH8,H7 = 6.5 Hz, 3 H, H8) ppm. 13C NMR
(100 MHz, CDCl3): δ = 171.5 (1 C, C10), 109.3, 109.1 (2 C, C12,
C13), 96.5 (1 C, C1), 71.0 (1 C, C3), 70.9 (1 C, C2), 70.7 (1 C, C4),
66.0 (1 C, C5), 64.9 (1 C, C7), 56.6 (1 C, C6), 26.0, 25.9, 25.1, 24.1
(4 C, CH3*4), 23.3 (1 C, C11), 20.4 (1 C, C8) ppm. IR (disc, KBr):
ν = 3600–3050 (OH), 1651 (amide), 1556 (NH amide), 1456, 1381,
˜
1373 [C(CH3)2] cm–1. HRMS: calcd. for C16H28NO7 [M + H]+
346.1866; found 346.1859.
Conclusions
In conclusion, we have reported here a convenient and
stereoselective preparation of 14-d-erythro, the active epi-
mer, and its C-6 epimer 14-d-threo by using aminodiol 9 as
a key chiral intermediate. The stereochemistry of com-
pounds 14-d-erythro, 14-d-threo, and 9-l-erythro was con-
firmed by X-ray analysis.[30] All four possible diastereomers
of aminodiol 9, that is, d-erythro, l-threo, l-erythro, and d-
threo, were successfully prepared by stereoselective re-
duction of corresponding α-keto esters 8 with either cate-
cholborane or NaBH3CN followed by reduction of the re-
sulting α-hydroxy esters 10 to desired aminodiols 9 with
LiAlH4.
The route presented here constitutes an important syn-
thetic potential for the rapid and completely stereoselective
preparation of lincosamine 14-d-erythro and its epimers,
which, without a doubt, can find application as useful
building blocks in the construction of lincosamine-based
antibiotics.
6-N-Acetylamino-6,8-didesoxy-1,2:3,4-di-O-isopropylidene-
D-
erythro-α- -galacto-1,5-octopyranose (14- -erythro): Prepared from
D
D
12-d-erythro (157 mg, 0.32 mmol) using the general hydrogenation–
acetylation protocol described above (1 bar of H2 for 15 h) to ob-
tain intermediate 13-d-erythro (98 mg, 100%). Next, 13-d-erythro
(98 mg, 0.32 mmol) was acetylated to afford 14-d-erythro (91 mg,
82%) as a white solid. M.p. 162–163 °C (ref.[31] 164–167 °C). Rf =
0.25 (EtOAc/MeOH, 19:1). [α]2D3 = –51.0 (c = 0.44, CHCl3) {ref.[31]
[α]2D3 = –52.9 (c = 2.25, CHCl3)}. H NMR (400 MHz, CDCl3): δ
1
= 6.48 (d, JH9,H6 = 7.1 Hz, 1 H, H9), 5.53 (d, JH1,H2 = 5.1 Hz, 1
H, H1), 4.61 (dd, JH3,H4 = 8.1 Hz, JH3,H2 = 2.3 Hz, 1 H, H3), 4.45
(dd, JH4,H3 = 8.1 Hz, JH4,H5 = 1.3 Hz, 1 H, H4), 4.30 (dd, JH2,H1
= 5.1 Hz, JH2,H3 = 2.3 Hz, 1 H, H2), 4.17–4.10 (m, 2 H, H5, H6),
4.07–4.00 (m, 1 H, H7), 1.99 (s, 3 H, H11), 1.52 (s, 3 H, CH3), 1.50
(s, 3 H, CH3), 1.35 (s, 3 H, CH3), 1.32 (s, 3 H, CH3), 1.25 (d, JH8,H7
= 6.6 Hz, 3 H, H8) ppm. 13C NMR (100 MHz, CDCl3): δ = 170.6
(1 C, C10), 109.4, 108.9 (2 C, C12, C13), 96.7 (1 C, C1), 72.1 (1 C,
C4), 71.0 (1 C, C3), 70.6 (1 C, C2), 68.4 (1 C, C7), 65.6 (1 C, C5),
57.0 (1 C, C6), 26.0, 25.9, 25.0, 24.2 (4 C, CH3*4), 23.5 (1 C, C11),
20.1 (1 C, C8) ppm. IR (disc, KBr): ν
= 3600–3000 (OH), 1660
˜
max
(amide), 1531 (NH amide), 1460, 1381 [C(CH3)2] cm–1. HRMS:
calcd. for C16H27NO7 [M]+ 345.1788; found 345.1788.
Experimental Section
General Procedure for the Hydrogenation–Acetylation of 12 Leading
to Products 14: To a solution of compound 12 in MeOH (22.0 mL)
was added Pd/C (10%), and the resulting reaction mixture was
stirred under an atmosphere of H2 for the required period of time
(see below). After completion of the reaction, the resulting mixture
was filtered through a pad of Celite, and the filtrate was concen-
trated under reduced pressure to afford 13 with a free amino group.
Those intermediates were unstable and, therefore, were immediately
acetylated using the following procedure. To a solution of crude
intermediate 13 (1 equiv.) in a mixture of dioxane (9.0 mL) and
H2O (11.0 mL) was added NaHCO3 (2.5 equiv.) and acetic anhy-
dride (2 equiv.). The resulting reaction mixture was vigorously
stirred for 1 h at room temperature and then the excess amount
of acetic anhydride was removed by co-evaporation with toluene.
Resulting crude acetylated products 14 were purified by column
chromatography.
Supporting Information (see footnote on the first page of this arti-
cle): General methods, experimental details, and characterization
data.
[1] a) S. Knapp, P. J. Kukkola, J. Org. Chem. 1990, 55, 1632–1636;
b) G. B. Howarth, W. A. Szarek, J. K. N. Jones, J. Chem. Soc.
C 1970, 2218–2224 and references cited therein.
[2] a) G. Slomp, F. A. Mackeller, J. Am. Chem. Soc. 1967, 89,
2454–2459; b) B. J. Magerlein, R. D. Birkenmeyer, R. R. Herr,
F. Kagan, J. Am. Chem. Soc. 1967, 89, 2459–2464.
[3] B. J. Magerlein, Tetrahedron Lett. 1970, 11, 33–36.
[4] a) S. Czernecki, J. M. Valéry, Carbohydr. Res. 1988, 184, 121–
130; b) M. A. Fontes Prado, J. Alves, A. Braga de Oliveira, J.
Dias de Souza Filho, Synth. Commun. 1996, 26, 1015–1022.
[5] H. Saeki, E. Ohki, Chem. Pharm. Bull. 1970, 18, 789–802.
[6] a) G. B. Howarth, D. G. Lance, W. A. Szarek, Can. J. Chem.
1969, 47, 75–79; b) G. R. Woolard, E. B. Rathbone, W. A. Sza-
rek, J. K. N. Jones, J. Chem. Soc. Perkin Trans. 1 1976, 950–
954.
6-N-Acetylamino-6,8-didesoxy-1,2:3,4-di-O-isopropylidene-
D-threo-
α- -galacto-1,5-octopyranose (14- -threo): Prepared from 12-d-
D
D
1846
www.eurjoc.org
© 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2011, 1841–1847